Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Holding DXCM?
Track your performance easily
DXCM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.34 - $142.00
Previous Close$77.83
Volume4.14M
Average Volume (3M)4.37M
Market Cap
$30.40B
Enterprise Value$32.31B
Total Cash (Recent Filing)$621.20M
Total Debt (Recent Filing)$2.53B
Price to Earnings (P/E)46.7
Beta0.85
Next Earnings
Feb 06, 2025EPS Estimate
$0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding390,595,390
10 Day Avg. Volume4,371,872
30 Day Avg. Volume4,367,870
Standard Deviation0.15
R-Squared0.16
Alpha0.00727
Financial Highlights & Ratios
Price to Book (P/B)14.84
Price to Sales (P/S)7.40
Price to Cash Flow (P/CF)36.70
P/FCF Ratio80.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.17
Enterprise Value/Gross Profit14.12
Enterprise Value/Ebitda33.20
Forecast
1Y Price Target
$95.19Price Target Upside22.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Dexcom News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDXCM reported 3Q results which were slightly ahead of Street revenue and EPS expectations.
International GrowthInternational revenue of $292M grew 16% y/y organic and exceeded projected $253M/Street's $268M.
Product Launch And Market ExpansionDXCM launched new products like Stelo OTC, G7 in Australia, and Dexcom ONE+ in France, indicating strong product pipeline progress.
Bears Say
Investor ConcernsSofter US performance in Q3 makes it tougher in the near-term to assuage investor fears of a slowing market.
Market Share LossDXCM lost incremental market share in the DME channel compared to 2Q24, contributing to a 2% year-over-year decline in U.S. revenue.
Revenue DeclineDXCM's 2% U.S. revenue decline in 3Q was several points worse than analysts expected, and with U.S. price/mix headwinds spiking to an all-time high, it could be at least several quarters before DXCM's U.S growth returns to double-digits.
---
Ownership Overview
0.43% Insiders
31.58% Mutual Funds
27.87% Other Institutional Investors
12.35% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $62.34 and its highest was $142.00 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 06, 2025 which is in 71 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 24, 2024. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.435 by $0.015.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.52.
How many shares outstanding does Dexcom have?
Dexcom has 390,595,400 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.45 in its last earnings report, beating expectations of $0.435. Following the earnings report the stock price went down -1.884%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 692M.
---
Dexcom Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$95.19 (22.13% Upside)
$95.19 (22.13% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 78%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.09%
12-Months-Change
Fundamentals
Return on Equity
32.06%
Trailing 12-Months
Asset Growth
-3.67%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
DXCM Company Deck
---
DXCM Earnings Call
Q3 2024
0:00 / 0:00
---
DXCM Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$95.19
▲(22.13% Upside)
Technical Analysis
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
33/46 ratings generated profit
1 Year Average Return
+37.80%
assigned a buy rating last month
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 71.74% of your transactions generating a profit, with an average return of +37.80% per trade.
---